| Misonix Announces Exclusive Supply Agreement With MedAssets For BoneScalpel And SonicOne O.R. | FARMINGDALE, N.Y., April 29, 2015 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced it has entered into an exclusive three-year national supply contract with MedAssets, one of the nation's largest third-party providers of supply chain management and procurement capabilities. MedAssets manages approximately $59 billion in annual supply spend on behalf of its clients.
"With MedAssets serving four out of five U.S. hospitals and approximately 123,000 non-acute healthcare providers, we are very excited to enter into this exclusive agreement for our BoneScalpel and SonicOne surgical technologies. This is simply a great opportunity for many more healthcare facilities and their patients to ultimately benefit from our technology," commented Michael A McManus, President and CEO of Misonix.
About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.
Safe Harbor Statement
|
